Table 2.
Patient characteristics
| Total (n = 35) | Unsuccessful transition† (n = 13) | Successful transition (n = 22) | p value‡ | |
|---|---|---|---|---|
| Age at diagnosis (years), (median, IQR) | 13 (12–15) | 14 (11.5–15.0) | 13 (12.0–15.0) | 0.875 |
| Months in transition clinic before transfer (median, IQR) | 13 (5–18) | 10 (5.0–18.0) | 13 (4.8–17.8) | 0.811 |
| Disease duration at transfer (median, IQR) | 7 (7–10) | 4.1 (3.0–6.9) | 4.5 (2.9–6.1) | 0.864 |
| Years after transfer at inclusion in study | ||||
| <2 | 2 (5.7%) | 1 (7.7%) | 1 (4.5%) | 1.0 |
| 2–4 | 20 (57.1%) | 7 (53.8%) | 13 (59.1%) | |
| 4–6 | 13 (37.1%) | 5 (38.5%) | 8 (36.4%) | |
| Gender (male), no. (%) | 15 (42.9%) | 3 (23.1%) | 12 (54.5%) | 0.070 |
| Disease type, CD, no. (%) | 24 (68.6%) | 9 (69.2%) | 15 (68.2%) | 1.0 |
| Medication at transfer* | ||||
| Aminosalicylates | 9 (25.7%) | 3 (23.1%) | 6 (27.2%) | 0.840 |
| Immunomodulators | 25 (71.4%) | 9 (69.2%) | 16 (72.7%) | |
| Anti‐TNF | 12 (34.2%) | 5 (38.5%) | 7 (31.8%) | |
| Prednisone | 2 (5.7%) | 1 (7.7%) | 1 (4.5%) | |
| No medication | 1 (2.9%) | 0 | 1 (4.5%) | |
| Active disease during transfer | 5 (14.3%) | 4 (30.8%) | 1 (4.5%) | 0.052 |
| Relapse within first year after transfer | 10 (28.6%) | 5 (38.5%) | 5 (22.7%) | 0.444 |
| Educational level | ||||
| Low | 16 (45.7%) | 7 (53.8%) | 9 (40.1%) | 0.467 |
| Medium | 13 (37.2%) | 3 (23.1%) | 10 (45.5%) | |
| High | 6 (17.1%) | 3 (23.1%) | 3 (13.6%) | |
Percentages are displayed as column percentages.
*Some patients were prescribed more than one kind of medication
†Moderately successful and failed transition
‡Successful vs unsuccessful transition.